Metabotropic Glutamate Receptor 7: A New Therapeutic Target in Neurodevelopmental Disorders
Neurodevelopmental disorders (NDDs) are characterized by a wide range of symptoms including delayed speech, intellectual disability, motor dysfunction, social deficits, breathing problems, structural abnormalities, and epilepsy. Unfortunately, current treatment strategies are limited and innovative...
Main Authors: | Nicole M. Fisher, Mabel Seto, Craig W. Lindsley, Colleen M. Niswender |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-10-01
|
Series: | Frontiers in Molecular Neuroscience |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fnmol.2018.00387/full |
Similar Items
-
Corrigendum: Metabotropic Glutamate Receptor 7: A New Therapeutic Target in Neurodevelopmental Disorders
by: Nicole M. Fisher, et al.
Published: (2018-12-01) -
Targeting metabotropic glutamate receptors for novel treatments of schizophrenia
by: James Maksymetz, et al.
Published: (2017-04-01) -
Role of the G Protein-Coupled Receptor, mGlu1, in Melanoma Development
by: Janet Wangari-Talbot, et al.
Published: (2010-08-01) -
Antipsychotic profiles of TASP0443294, a novel and orally active positive allosteric modulator of metabotropic glutamate 2 receptor
by: Hirohiko Hikichi, et al.
Published: (2015-03-01) -
Computational Drug Design Applied to the Study of Metabotropic Glutamate Receptors
by: Claudia Llinas del Torrent, et al.
Published: (2019-03-01)